Geneva, March 20 -- International Clinical Trials Registry received information related to the study (NCT07454369) titled 'Comparative Bioavailability Study Between Etoricoxib / Betamethasone Administered Individually or in Combination' on Feb. 25.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Laboratorios Silanes S.A. de C.V.
Condition:
Healthy
Intervention:
Drug: A1: Etoricoxib / Betamethasone in fixed dose combination tablet. (Laboratorios Silanes S.A. de C.V.)
Drug: A2: Etoricoxib (Arcoxia(R), Laboratorios Schering-Plough, S.A. de C.V.)
Recruitment Status: Not recruiting
Phase: Phase 1
Date...